Overview

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Status:
Completed

Trial end date:
2019-03-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and efficacy of oral lenvatinib in participants with medullary thyroid cancer (MTC) or radioiodine (131 I)-refractory/resistant differentiated thyroid cancer (DTC), unresectable differentiated thyroid cancers, stratified by Histology.

Phase:

Phase 2

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Lenvatinib